CHELSEY BAKKER: Open Payments
NPI 1932818465 · TULSA, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,483 in 82 payments from 20 companies in 2025. Trend: 2023 $948 · 2024 $2,222 · 2025 $2,483
Food & beverage: $2,439Education: $42Travel & lodging: $2
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 19 | $570 |
| AstraZeneca Pharmaceuticals LP | 11 | $553 |
| Genentech USA, Inc. | 5 | $168 |
| Novartis Pharmaceuticals Corporation | 6 | $157 |
| Genentech, Inc. | 2 | $151 |
| CSL Behring | 8 | $139 |
| Blueprint Medicines Corporation | 1 | $122 |
| Regeneron Healthcare Solutions, Inc. | 4 | $90 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Amgen Inc. | 3 | $76 |
Products named: DUPIXENT, Xolair, BEVESPI AEROSPHERE, FASENRA, TEZSPIRE, AYVAKIT, NEFFY, NEMLUVIO.
Industry payments across OK — which companies pay providers there.
